Min Wu
Research Subjects
Min Wu has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Yang Liu
Department of Pharmacology and Toxicology, Innovent Guoqing Academy, Suzhou, China
16 shared publications - ZhiHai Wu
Department of Antibody Discovery and Protein Engineering, Innovent Guoqing Academy, Suzhou, China
16 shared publications - Bing Wu
Innovent Biologics (Suzhou) Co., Ltd., Suzhou, China
15 shared publications - Fufan He
Innovent Biologics (Suzhou) Co., Ltd., Suzhou, China
15 shared publications - Haiqing Ni
Innovent Biologics (Suzhou) Co., Ltd., Suzhou, China
15 shared publications - Huan Zhang
Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
15 shared publications
Latest Publications
- 21 September 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- p. OF1-OF18
The Trispecific Antibody IBI3019 Integrates CDH17-Enhanced EGFR Antagonism with Optimized CD16A Engagement to Elicit Potent Antitumor Activity with Minimal Toxicity
Potent and sustained inhibition of epidermal growth factor receptor (EGFR) signaling is critical for suppressing colorectal cancer growth, yet current EGFR therapies are often limited by incomplete EGFR blockade and on-target/off-tumor toxicities, particularly skin rash. In this study, we cotargeted EGFR and cadherin-17 (CDH17) with a bispecific antibody (bsAb), overcoming these limitations by reducing skin-related toxicities and achieving superior tumor growth inhibition compared with EGFR- or c-Met/EGFR-targeting antibodies. Mechanistically, the high-affinity CDH17-binding arm anchored the EGFR/CDH17 bsAb to the tumor-cell surface, facilitating rapid engagement of unbound or newly synthesized EGFR. This “anchor and capture” mechanism allowed the EGFR/CDH17 bsAb to achieve superior and more sustained suppression of the EGFR pathway than cetuximab and amivantamab. Further incorporation of an anti-CD16A nanobody transformed the EGFR/CDH17 bsAb into a trispecific natural killer (NK) cell engager. Extensive format screening revealed that NK-cell activation is heavily influenced by the spatial distance between the tumor antigen–binding Fab and the anti-CD16A nanobody, with longer distances impairing the bulky CD45 phosphatase exclusion from the immunologic synapse and leading to significantly reduced cytotoxicity. Consequently, the widely adopted Morrison-type antibody consistently underperformed compared with architectures with shorter CD16A–tumor-associated antigen (TAA)–Fab spacing. The final optimized molecule was IBI3019, a CDH17/EGFR/CD16A trispecific antibody that integrates potent CDH17-enhanced EGFR blockade with optimal architecture for efficient NK-cell engagement. It demonstrated superior in vivo efficacy and a good safety profile in cynomolgus monkeys, with no observable skin toxicity. These promising preclinical findings warrant the clinical development of IBI3019. Significance: IBI3019 integrates two key underappreciated mechanisms for potent anti-EGFR therapy: the “anchor and capture” strategy for enhanced EGFR antagonism and the necessity of a narrow immunological synapse for optimal ADCC.
- 21 September 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- p. OF1-OF18
The Trispecific Antibody IBI3019 Integrates CDH17-Enhanced EGFR Antagonism with Optimized CD16A Engagement to Elicit Potent Antitumor Activity with Minimal Toxicity
Potent and sustained inhibition of epidermal growth factor receptor (EGFR) signaling is critical for suppressing colorectal cancer growth, yet current EGFR therapies are often limited by incomplete EGFR blockade and on-target/off-tumor toxicities, particularly skin rash. In this study, we cotargeted EGFR and cadherin-17 (CDH17) with a bispecific antibody (bsAb), overcoming these limitations by reducing skin-related toxicities and achieving superior tumor growth inhibition compared with EGFR- or c-Met/EGFR-targeting antibodies. Mechanistically, the high-affinity CDH17-binding arm anchored the EGFR/CDH17 bsAb to the tumor-cell surface, facilitating rapid engagement of unbound or newly synthesized EGFR. This “anchor and capture” mechanism allowed the EGFR/CDH17 bsAb to achieve superior and more sustained suppression of the EGFR pathway than cetuximab and amivantamab. Further incorporation of an anti-CD16A nanobody transformed the EGFR/CDH17 bsAb into a trispecific natural killer (NK) cell engager. Extensive format screening revealed that NK-cell activation is heavily influenced by the spatial distance between the tumor antigen–binding Fab and the anti-CD16A nanobody, with longer distances impairing the bulky CD45 phosphatase exclusion from the immunologic synapse and leading to significantly reduced cytotoxicity. Consequently, the widely adopted Morrison-type antibody consistently underperformed compared with architectures with shorter CD16A–tumor-associated antigen (TAA)–Fab spacing. The final optimized molecule was IBI3019, a CDH17/EGFR/CD16A trispecific antibody that integrates potent CDH17-enhanced EGFR blockade with optimal architecture for efficient NK-cell engagement. It demonstrated superior in vivo efficacy and a good safety profile in cynomolgus monkeys, with no observable skin toxicity. These promising preclinical findings warrant the clinical development of IBI3019. Significance: IBI3019 integrates two key underappreciated mechanisms for potent anti-EGFR therapy: the “anchor and capture” strategy for enhanced EGFR antagonism and the necessity of a narrow immunological synapse for optimal ADCC.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
Supplementary Figure S7: Epitope binning of indicated CD47 antibodies by biolayer interferometry.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
Supplementary Figure S7: Epitope binning of indicated CD47 antibodies by biolayer interferometry.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
Supplementary Figure S11: In vitro phagocytosis, in vivo anti-tumor efficacy, and body weight change data of TJH2201.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
Supplementary Figure S11: In vitro phagocytosis, in vivo anti-tumor efficacy, and body weight change data of TJH2201.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
Supplementary Figure S4: Hematological effects of biparatopic CD47 antibody, Hu5F9/B2B, in vitro and in vivo.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
Supplementary Figure S4: Hematological effects of biparatopic CD47 antibody, Hu5F9/B2B, in vitro and in vivo.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
Supplementary Table S1: Sequence of TJH2201 (hz145A2/hz176G1)
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
Supplementary Table S1: Sequence of TJH2201 (hz145A2/hz176G1)
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Data from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
The CD47/SIRPα axis serves as a “do not eat me” signal, protecting normal cells from phagocytosis, but in the meantime, enabling immune evasion by tumor cells. Whereas substantial progress has been made in developing CD47 antagonists, achieving a balance between hematotoxicity and antitumor efficacy remains a critical challenge. In this study, we demonstrated that the bivalent anti-CD47 antibody, Hu5F9, caused severe anemia in both human CD47 knock-in mice lacking the CD47/SIRPα signal and human CD47/SIRPα double knock-in mice with complete signal, suggesting the CD47/SIRPα signal is not essential. Moreover, the single-arm CD47 antibody Hu5F9/gp120 exhibited only mild red blood cell (RBC) destruction in vitro and in vivo. These findings reveal that RBC toxicity induced by anti-CD47 antibodies is determined by the bivalency of the antibody rather than the CD47/SIRPα signal engagement. Based on this, we engineered TJH2201, a novel anti-CD47 antibody that avoids RBC agglutination while retaining high-affinity CD47 binding, robust signaling blockade, and enhanced pro-phagocytosis activity in vitro. In xenograft models with Raji and MV-4-11 cells, TJH2201 demonstrated potent antitumor activity without inducing body weight loss. These results suggest that TJH2201 is a promising CD47 antagonist that balances antitumor efficacy and hematologic safety, providing a new therapeutic approach for CD47-expressing malignancies.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
The CD47/SIRPα axis serves as a “do not eat me” signal, protecting normal cells from phagocytosis, but in the meantime, enabling immune evasion by tumor cells. Whereas substantial progress has been made in developing CD47 antagonists, achieving a balance between hematotoxicity and antitumor efficacy remains a critical challenge. In this study, we demonstrated that the bivalent anti-CD47 antibody, Hu5F9, caused severe anemia in both human CD47 knock-in mice lacking the CD47/SIRPα signal and human CD47/SIRPα double knock-in mice with complete signal, suggesting the CD47/SIRPα signal is not essential. Moreover, the single-arm CD47 antibody Hu5F9/gp120 exhibited only mild red blood cell (RBC) destruction in vitro and in vivo. These findings reveal that RBC toxicity induced by anti-CD47 antibodies is determined by the bivalency of the antibody rather than the CD47/SIRPα signal engagement. Based on this, we engineered TJH2201, a novel anti-CD47 antibody that avoids RBC agglutination while retaining high-affinity CD47 binding, robust signaling blockade, and enhanced pro-phagocytosis activity in vitro. In xenograft models with Raji and MV-4-11 cells, TJH2201 demonstrated potent antitumor activity without inducing body weight loss. These results suggest that TJH2201 is a promising CD47 antagonist that balances antitumor efficacy and hematologic safety, providing a new therapeutic approach for CD47-expressing malignancies.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
Supplementary Figure S10: HE staining of spleens from hCD47/SIRPα KI mice 4 days after treatment.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
Supplementary Figure S10: HE staining of spleens from hCD47/SIRPα KI mice 4 days after treatment.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
Supplementary Figure S2: Binding ability and in vitro human RBC agglutination assay of Hu5F9/gp120.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
Supplementary Figure S2: Binding ability and in vitro human RBC agglutination assay of Hu5F9/gp120.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
Supplementary Figure S1: Hematological effects of Hu5F9 on hCD47 KI mice and hCD47/SIRPα DKI mice.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
Supplementary Figure S1: Hematological effects of Hu5F9 on hCD47 KI mice and hCD47/SIRPα DKI mice.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
Supplementary Figure S6: Microscopic images of in vitro RBC agglutination induced by Hu5F9/B2B at concentrations from 0.046 µg/ml to 100 µg/ml. Scale bar = 100 µm
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
Supplementary Figure S6: Microscopic images of in vitro RBC agglutination induced by Hu5F9/B2B at concentrations from 0.046 µg/ml to 100 µg/ml. Scale bar = 100 µm